# Phase 6 Answer Examples

Real outputs from the frozen `candidate_b_structured` architecture (Cerebras `qwen-3.8-27b`) against real Evidence built from Phase-5 benchmark manifest records. No chain-of-thought is stored or shown - only the final rendered answer and its compiled citations/references.

## PubMed — `P6-D1`

**Question:** What clinical evidence supports brigatinib for ALK-positive advanced NSCLC?

**Answer:**

Brigatinib has demonstrated high activity and durable responses in patients with ALK-positive advanced NSCLC who are resistant to crizotinib, including in intracranial disease.[1] Brigatinib is effective against various ALK resistance mutations, such as G1269A, C1156Y, I1171S/T, and V1180L.[1] The FDA has approved brigatinib for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.[1] As a first-line treatment for ALK-positive advanced NSCLC, brigatinib demonstrates superior progression-free survival (PFS) compared to chemotherapy or crizotinib.[2] Clinical evidence supports brigatinib as a therapeutic option for ALK-positive advanced NSCLC in both the second-line setting (post-crizotinib) and the first-line setting, with demonstrated efficacy in both systemic and intracranial disease.[1][2]

**Claims:** 5 (4 factual) | **Citations:** 2 | **References:** 2 | **Abstained:** False | **Conflict detected:** False

---

## ClinicalTrials — `P6-D2`

**Question:** What is the status and phase of the brigatinib trial NCT03535740?

**Answer:**

The status of the brigatinib trial NCT03535740 is COMPLETED.[1] The phase of the brigatinib trial NCT03535740 is PHASE2.[1]

**Claims:** 2 (2 factual) | **Citations:** 1 | **References:** 1 | **Abstained:** False | **Conflict detected:** False

---

## ChEMBL — `P6-D3`

**Question:** What is imatinib's ChEMBL identifier?

**Answer:**

Imatinib's ChEMBL identifier is CHEMBL941.[1]

**Claims:** 1 (1 factual) | **Citations:** 1 | **References:** 1 | **Abstained:** False | **Conflict detected:** False

---

## Multi-source — `P6-D4`

**Question:** Summarize what published literature and clinical trials say about brigatinib for ALK-positive NSCLC.

**Answer:**

Brigatinib is active against various ALK resistance mutations, including G1269A, C1156Y, I1171S/T, and V1180L.[1] Clinical trials have confirmed that brigatinib has high activity and durable response in crizotinib-resistant patients, including in intracranial disease.[1] Brigatinib received FDA approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.[1] A completed Phase 2 clinical trial (NCT03535740) evaluated brigatinib in 103 patients with ALK-positive advanced NSCLC who had progressed on alectinib or ceritinib.[2] The primary purpose of the NCT03535740 trial was to determine the efficacy of brigatinib by confirmed objective response rate (ORR) using RECIST criteria.[2] The literature and clinical trials indicate that brigatinib is being evaluated and utilized in multiple lines of therapy for ALK-positive NSCLC, including after crizotinib, alectinib, and ceritinib.[1][2]

**Claims:** 6 (5 factual) | **Citations:** 2 | **References:** 2 | **Abstained:** False | **Conflict detected:** False

---

## Insufficient evidence — `P6-D5`

**Question:** What is the recommended pediatric dosing schedule for brigatinib?

**Answer:**

The provided evidence does not contain information regarding the recommended pediatric dosing schedule for brigatinib.

**Claims:** 1 (0 factual) | **Citations:** 0 | **References:** 0 | **Abstained:** True | **Conflict detected:** False

---

## Conflicting/varying evidence — `P6-D7`

**Question:** What is the clinical development landscape for melanoma therapies recorded in ChEMBL?

**Answer:**

ChEMBL records indicate that melanoma therapies have reached a maximum clinical development phase of 4.0.[1] ChEMBL records indicate that melanoma therapies have reached a maximum clinical development phase of 3.0.[2] ChEMBL records indicate that melanoma therapies have reached a maximum clinical development phase of 1.0.[3] The clinical development landscape for melanoma therapies in ChEMBL spans early-stage (Phase 1) to approved (Phase 4) clinical trials.[1][2][3]

**Claims:** 4 (3 factual) | **Citations:** 3 | **References:** 3 | **Abstained:** False | **Conflict detected:** False

---
